SEC For	rm 4																
FORM 4 UNITED) STA	STATES SECURITIES AND EXCHANGE COMMISSI Washington, D.C. 20549										OMB A	PPRO	VAL
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					MENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								HIP	OMB Estima	Number: ated avera per respo	age burder	3235-0287
1. Name and Address of Reporting Person* <u>Moore Matthew Richard</u>						2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ARQT]								able) r (give title	10% O ve title Other (Owner (specify
	(Last) (First) (Middle) C/O ARCUTIS BIOTHERAPEUTICS, INC. 3027 TOWNSGATE ROAD, SUITE 300					3. Date of Earliest Transaction (Month/Day/Year) 03/03/2022								X Officer (give the Solider (Specify below) below) SVP and Chief Business Officer			
(Street) WESTLAKE VILLAGE CA 91361					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)																	
		Tab	ole I - Nor	n-Deriv	ative Se	ecurities Acq	uired,	Disp	oosed o	of, or	r Bene	eficiall	y Owned				
Da				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			(A) or 3, 4 and	4 and 5. Amount of Securities Beneficially Owned Follo Reported		Form: Direct (D) or Indirec		7. Nature of Indirect Beneficial Ownership
							Code	v	Amount		(A) or (D)	Price	Transact	Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common Stock 03/03					3/2022		Α		13,300)(1)	Α	\$ <mark>0</mark>	13,3	300 ⁽²⁾	D		
		-				urities Acqu Is, warrants,							Owned				
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date Execution Date if any		Date, T	l. Transaction Code (Instr. 3)	of I	6. Date Ex Expiration (Month/Da	Date	of Securities		ecurity	8. Price of Derivative Security (Instr. 5) Benefici Owned Followin Reporte Transac		e Ov s Fo Ily Di or J (I)). wnership orm: irect (D) r Indirect) (Instr. 4)	11. Nature of Indirect Beneficial Ownershi (Instr. 4)		

					3, 4 and 5)							(Instr. 4)		
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$17.67	03/03/2022	A		35,300		(3)	03/03/2032	Common Stock	35,300	\$0.00	35,300	D	

Explanation of Responses:

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2023, subject to the Reporting Person's continued service to the Issuer.

2. Includes 13,300 RSUs.

3. 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

<u>/s/ Scott Burrows, as Attorney-</u>	
in-Fact for Matthew Richard	03/07/2022
Moore	

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.